Literature DB >> 21264801

Apelin serum levels are not associated with early atherosclerosis or fat distribution in young subjects with increased risk for type 2 diabetes.

K Rittig1, U Hildebrandt, C Thamer, H Staiger, A Peter, N Stefan, A Fritsche, H-U Häring, B M Balletshofer, D Siegel-Axel.   

Abstract

Apelin is proposed to possess protective cardiovascular properties and may furthermore promote favorable effects on glucose metabolism. First data in humans seem to support this hypothesis. Therefore we aimed to assess the meaning of apelin as an early risk indicator in young subjects prone to atherosclerosis and type 2 diabetes. Furthermore we examined the association of apelin serum levels with insulin sensitivity/resistance and body fat distribution as probably dependent cardiovascular risk factors. We examined 344 individuals (f/m=216/128, mean age 46±1 years) with an increased risk for type 2 diabetes. Apelin-36 serum levels were measured via ELISA. Endothelial dysfunction and intima media thickness (IMT) were assessed using high resolution ultrasound. Visceral adipose tissue (VAT) was measured with an axial T1-weighted fast spin echo technique with a 1.5 T whole-body imager. According to the study population's age, FMD (6.4±0.2%) and IMT (0.56±0.01 mm) were within the expected ranges. Gender or age had no influence on serum apelin levels. When looked at early stages of atherosclerosis, we could not detect a significant correlation between apelin serum levels and FMD or IMT. Blood pressure as well was unaffected by serum apelin levels. Furthermore, neither parameters of insulin sensitivity like insulin sensitivity index (ISI), nor fat distribution like BMI, grade of adiposity, total adipose tissue or VAT were associated with apelin serum levels. We conclude that apelin serum levels do not add further information on the cardiovascular-, or diabetes risk pattern in a diabetes prone population. © J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21264801     DOI: 10.1055/s-0030-1268466

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  6 in total

Review 1.  Adipose tissue and vascular inflammation in coronary artery disease.

Authors:  Enrica Golia; Giuseppe Limongelli; Francesco Natale; Fabio Fimiani; Valeria Maddaloni; Pina Elvira Russo; Lucia Riegler; Renatomaria Bianchi; Mario Crisci; Gaetano Di Palma; Paolo Golino; Maria Giovanna Russo; Raffaele Calabrò; Paolo Calabrò
Journal:  World J Cardiol       Date:  2014-07-26

2.  Targeting the ACE2 and Apelin Pathways Are Novel Therapies for Heart Failure: Opportunities and Challenges.

Authors:  Seyyed M R Kazemi-Bajestani; Vaibhav B Patel; Wang Wang; Gavin Y Oudit
Journal:  Cardiol Res Pract       Date:  2012-05-13       Impact factor: 1.866

3.  The Effect of Estrogen Replacement Therapy on Visceral Fat, Serum Glucose, Lipid Profiles and Apelin Level in Ovariectomized Rats.

Authors:  Parvin Babaei; Adele Dastras; Bahram Soltani Tehrani; Shiva Pourali Roudbaneh
Journal:  J Menopausal Med       Date:  2017-12-29

4.  Serum Apelin: A New Marker of Early Atherosclerosis in Children with Type 1 Diabetes Mellitus.

Authors:  Rania N Sabry; Maged A El Wakeel; Ghada M El-Kassas; Ahmed F Amer; Wael H El Batal; Salwa Refat El-Zayat; Mohamed Abou-El-Asrar
Journal:  Open Access Maced J Med Sci       Date:  2018-04-04

5.  Serum Apelin and Obesity-Related Complications in Egyptian Children.

Authors:  Maged A El Wakeel; Ghada M El-Kassas; Alyaa H Kamhawy; Essam M Galal; Maysa S Nassar; Elsayed Mahmoud Hammad; Salwa Refat El-Zayat
Journal:  Open Access Maced J Med Sci       Date:  2018-08-17

6.  Connection between the Plasma Level of Apelin and Diabetic Nephropathy in Type 2 Diabetic Patients. A Case Control Study.

Authors:  Mona Yousry Helmy; Nehal Hamdy; Nagwa Abd El Ghaffar
Journal:  Indian J Endocrinol Metab       Date:  2022-01-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.